

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Duplicate Therapy	Cholesterol-Lowering Agents: HMG-CoA Inhibitors (statins)	Patients filling more than one drug within the same therapeutic class concurrently.	Y	3/20/2013	Patients allowed one drug at a time within the class.
Drug Shortage	Tetracycline Antibiotics	Drug shortages increased price of available doxycycline products.	N	3/20/2013	Prior authorization required to obtain doxycycline.
Inappropriate Use	Topical Antibiotics and Benzoyl Peroxide Formulations for Treating Acne	Patients receiving topical preparations for the treatment of acne outside of recommendations.	N	2/25/2013	Prior authorization required for topical acne products if patient is less than 10 years of age or older than 20 years of age.
Duplicate Therapy	Inhaled Glucocorticoids	Patients filling single-agent glucocorticoid inhaler in combination with a combination agent glucocorticoid inhaler concomitantly.	Y	2/5/2013	Patients allowed only one inhaled glucocorticoid at one time, regardless of whether it is a single-agent or combination product.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Drug-Drug Interaction	Cholesterol-Lowering Agents: Gemfibrozil and Simvastatin	Patients filling both agents concomitantly. Combination is contraindicated due to an increased risk of muscle damage*.	Y	2/5/2013	Patients not allowed to fill gemfibrozil and simvastatin in the same 30-day period.
Inappropriate Therapy	Narcotics: Tramadol and Tramadol Combination Products	Patients filling multiple narcotics in large quantities.	Y	2/5/2013	Maximum monthly quantity of 186, which already applied to certain other narcotics, applied to tramadol.
Inappropriate Use	Narcotic Antagonists (Suboxone [®] / buprenorphine)	Patients filling Suboxone [®] / buprenorphine without adherence to complete treatment program.	Y	2/1/2013	Patients allowed 12 months of (Suboxone [®] / buprenorphine). Enhanced prior authorization guidelines require documented adherence to a complete treatment program. Enhanced guidelines educate providers on availability of DASA services.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Duplicate Therapy	Oral Multiple Sclerosis Medications	Patients filling more than one drug within the same therapeutic class concurrently.	Y	1/31/2013	Patients allowed one drug at a time within the class.
Duplicate Therapy	Long-Acting Injectable Contraceptives	Patients filling multiple injectable long-acting contraceptives concurrently.	N	12/18/2012	Patients allowed one long-acting injectable contraceptive per 3-month period.
Inappropriate Therapy	Blood Factor Products	Pharmacies dispensing blood factor when patient has sufficient blood factor on hand to meet their treatment needs.	N	12/10//2012	Providers who dispense blood factor sign a Standards of Care Agreement. Prior authorization allows HFS the opportunity to ensure appropriateness of therapy, compliance with therapy, and decrease of potential wastage. HFS works with prescribers to intervene in cases of patient non-compliance.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Duplicate Therapy	Angiotensin Converting Enzyme Inhibitors (ACEIs)	Patients receiving two strengths of a drug or receiving two different drugs within the same class concurrently.	Y	12/10/2012	Patients allowed one drug/one strength of a drug within the class at one time.
Duplicate Therapy	Angiotensin Receptor Blockers (ARBs)	Patients receiving two strengths of a drug or two different drugs within the same class concurrently.	Y	12/10/2012	Patients allowed one drug/one strength of a drug within the class at one time.
Inappropriate Therapy	Narcotics: Tramadol	Patients filling tramadol while taking the narcotic antagonist Suboxone.	Y	11/12/2012	Patients taking Suboxone may not fill prescriptions for opioids/tramadol concurrently.
Duplicate/ Unnecessary Therapy	Blood Glucose Meters	Patients filling multiple blood glucose meters within a year.	N	10/25/2012	A subsequent claim will reject if the patient has already filled a prescription for a blood glucose meter.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Duplicate/ Unnecessary Therapy	Asthma Spacers	Patients filling spacers each month.	N	10/20/2012	A subsequent claim will reject if the patient has already filled a prescription for a spacer.
Duplicate Therapy	Anxiolytics	Patients filling clonazepam in addition to other benzodiazepine anxiolytics concurrently.	Y	10/15/2012	Prior approval is required for patients to receive clonazepam concurrently with other benzodiazepine anxiolytics. Other anxiolytics were already subject to duplicate therapy editing.
Duplicate Therapy	Insulin	Patients filling multiple prescriptions for the same insulin in different delivery systems, e.g., pens and vials.	Y	10/8/2012	A subsequent claim will reject as a duplicate if the patient has already filled a prescription for the same insulin, regardless of delivery system.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Duplicate Therapy	Inhaled Corticosteroid/ Long-Acting Beta Agonist Combinations	Patients filling multiple strengths of same drug or multiple drugs concurrently.	Y	9/26/2012	Patients allowed only one strength of one drug in the class at one time.
Duplicate Therapy	Inhaled Corticosteroids	Patients filling multiple inhaled corticosteroids concurrently.	Y	9/26/2012	Patients allowed only one strength of one drug in the class at one time.
Inappropriate Therapy	Imiquimod 5% Cream	Imiquimod cream used for the treatment of plantar warts in children.	Y	9/24/12	Imiquoid cream restricted to adults 18 years of age and older with cancer or genital warts.
Duplicate Therapy	Oral Contraceptives	Patients filling multiple drugs within the same therapeutic class concurrently.	N	9/21/2012	Patients allowed only one drug at a time within the class.
Duplicate Therapy	Injectable Multiple Sclerosis Medications	Patients filling more than one drug within the same therapeutic class concurrently.	Y	9/20/2012	Patients allowed one drug at a time within the class.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Inappropriate Therapy	Erythropoietic Support Agents (ESA)	Patients prescribed ESA when hemoglobin level is > 11 g/dL..	Y	7/1/2012	Prior approval required to ensure therapy is consistent with treatment guidelines.
Inappropriate Therapy	Hepatitis C Agents	Patients prescribed Hepatitis C drugs inconsistent with treatment guidelines.	Y	7/1/2012	Prior approval required to ensure therapy is consistent with treatment guidelines.
Inappropriate Therapy	Select Cancer Medications	Patients prescribed oncolytic products for cancer and non-cancer indications inconsistent with treatment guidelines.	Y	7/1/2012	Prior approval required to ensure therapy is consistent with treatment guidelines.
Inappropriate Therapy	Immune Gamma Globulin	Patients prescribed immune gamma globulin inconsistent with treatment guidelines.	Y	7/1/2012	Prior approval required to ensure therapy is consistent with treatment guidelines.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Inappropriate Therapy	Antipsychotic Medications for Long-Term Care Residents	Antipsychotic medications prescribed to residents of Long-Term Care facilities inconsistent with treatment guidelines.	Y	6/1/2011	Prior approval required to ensure therapy is consistent with treatment guidelines.
Inappropriate Therapy	Lupron	Lupron prescribed inappropriately in children for short stature and autism.	Y	1/1/2011	Lupron age restricted and requires prior approval for children to ensure it is used appropriately.
Inappropriate Therapy	Hepatitis B Agents	Patients prescribed Hepatitis B drugs inconsistent with treatment guidelines.	Y	1/1/2011	Prior approval required to ensure therapy is consistent with treatment guidelines.
Inappropriate Therapy	Atypical Antipsychotics in Children Less Than 8 Years of Age	Medications prescribed for children inconsistent with treatment guidelines.	Y	8/24/2009	Prior approval required to ensure therapy is consistent with treatment guidelines.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013

Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Inappropriate Therapy	Medications for Attention Deficit Hyperactivity (ADHD) Disorder in Children Less Than 6 Years of Age	Medications overprescribed for ADHD in young children inconsistent with product labeling.	Y	8/24/2009	Prior approval required to ensure therapy is consistent with treatment guidelines.
Inappropriate Therapy	Antibiotics Cubicin [®] , Synercid [®] , Teflaro [®] , Tygacil [®] , Zyvox [®]	Patients prescribed new antibiotics inconsistent with treatment guidelines, potentially creating resistant bacteria and fewer treatment options.	Y	11/2007	Prior approval required to ensure therapy is consistent with treatment guidelines.
Inappropriate Therapy	Synagis [®] (palivizumab)	Patients prescribed Synagis inconsistent with American Academy of Pediatrics recommendations.	Y	8/19/2005	Prior approval required to ensure therapy is provided to patients who meet the criteria established by the AAP.

Select Claims Processing Drug Utilization Control Edits through May 8, 2013					
Problem Type	Drug Class(es)	Description of Problem	Potential for Serious Adverse Events (Y/N)	Begin Date of Edit	Brief Description of Edit
Inappropriate Therapy	Narcotics: Duragesic (fentanyl) Patches	Patients filling excessive quantities of fentanyl patches.	Y	3/23/2005	Patients able to receive a maximum of 15 patches per month (all strengths combined) without prior authorization.
Inappropriate Therapy	Sedative/Hypnotics	Patients using sedative/hypnotics continuously, inconsistent with treatment guidelines.	Y	3/1/2005	Patients able to receive 8 pills per month of preferred sedative/hypnotics without prior authorization.
Inappropriate Use	Topical Retinoid Formulations for Treating Acne	Patients receiving topical retinoid preparations for the treatment of acne outside of recommendations.	N	4/15/2002	Prior authorization required for topical retinoid acne products if patient is less than 10 years of age or older than 20 years of age.

* FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Updated December 15, 2011. Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm>.